Crossref
HPV Genotype as a Predictor of Bevacizumab Treatment Response in Recurrent Respiratory Papillomatosis Patients
ENT Discovery · 2025
DOI: 10.15302/entd.2025.090004 ↗Kurz gefasst
Fachartikel in der Zeitschrift ENT Discovery, 2025.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2025). HPV Genotype as a Predictor of Bevacizumab Treatment Response in Recurrent Respiratory Papillomatosis Patients. ENT Discovery. https://doi.org/10.15302/entd.2025.090004
Vancouver
HPV Genotype as a Predictor of Bevacizumab Treatment Response in Recurrent Respiratory Papillomatosis Patients. ENT Discovery. 2025. doi:10.15302/entd.2025.090004
BibTeX
@article{euvimed2025,
title = {HPV Genotype as a Predictor of Bevacizumab Treatment Response in Recurrent Respiratory Papillomatosis Patients},
journal = {ENT Discovery},
year = {2025},
doi = {10.15302/entd.2025.090004}
}
EUVIMED